Arrowhead Pharmaceuticals (ARWR) Profit After Tax (2010 - 2026)

Arrowhead Pharmaceuticals' Profit After Tax history runs 17 years deep, the most recent figure standing at -$139.1 million for Q1 2026.

• Quarterly Profit After Tax fell 137.52% year-over-year to -$139.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$274.0 million (down 72.07% YoY) and the FY2025 annual result came in at $30.1 million, up 104.94% from the prior year.
• Profit After Tax was -$139.1 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $28.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at $370.7 million in Q1 2025 and bottomed at -$180.7 million in Q3 2024.
• A 5-year average of -$59.9 million and a median of -$104.1 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax tumbled 366.37% — and 2025, when it jumped 391.9%.
• Arrowhead Pharmaceuticals' Profit After Tax stood at -$41.8 million in 2022, then plunged by 223.78% to -$135.4 million in 2023, then dropped by 29.43% to -$175.2 million in 2024, then soared by 116.12% to $28.2 million in 2025, then sank by 592.5% to -$139.1 million in 2026.
• Business Quant data shows ARWR's Profit After Tax at -$139.1 million in Q1 2026, $28.2 million in Q4 2025, and $15.5 million in Q3 2025.